Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Concord Biotech Limited

Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing.

The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.

Rising Tide

Quadria Capital

Neuberger Berman

Critically ill patients on ventilators face a high risk of lower respiratory tract infections, such as ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP). VAP is linked to increased morbidity and mortality in the ICU, emphasizing the need for prevention. 

This review examines the potential of pre-emptive aerosolized antibiotics (AA) in preventing ventilator-associated infections and whether aerosolized treatment for VAT can halt its progression to VAP. 

Read more: https://lnkd.in/dX6msByM 

#respiratoryinfections #ventilatorassociatedpneumonia #aerosolizedantibiotics #ventilatorassociatedtracheobronchitis #criticalcare #intensivecare

Concord Biotech stands united on World AIDS Day, spreading awareness and knowledge to foster a world free from HIV/AIDS. Together, let's strive for prevention, support, and a brighter, healthier future for all.

#WorldAIDSDAY2023
#WorldAIDSDay  #HIV #AIDS #HIVawareness #AIDSawareness

Tune in to today's episode of Good Health Conquest as we discuss the Role of the granzyme family in rheumatoid arthritis. Our spotlight turns to the granzyme family, specifically granzymes A, B, M, K, and the enigmatic granzyme H, shedding light on their potential role in rheumatoid arthritis pathogenesis.

Listen now: https://lnkd.in/d5UCpmhA
For more information, visit www.conquest.health

#RA #Rheumatoidarthritis #Granzyme #pathogenesis #podcast #Concordbiotech #GoodHealthConquest

On this Gurupurab, may the teachings of Guru Nanak Dev Ji inspire you to lead a life of compassion and righteousness. Happy Gurupurab!

#HappyGurupurab #Gurupurab #GuruNanakJayanti #HappyGuruNanakJayanti #ConcordBiotech

On today's episode of the Good Health Conquest, we discuss the Current Therapies in Kidney Transplant Rejection, specifically acute T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR). Stay tuned as we navigate the evolving landscape of kidney transplantation, striving for improved long-term outcomes and a deeper understanding of rejection mechanisms.

Listen now: https://lnkd.in/dU-xVv2q Find us on all major listening platforms and apps. For more information, visit our website at www.conquest.health

#kidneytransplant #renaltransplant #treansplantrejection #rejection #posttransplant #kidneycomplications #Concordbiotech

While there are chances to enhance antibiotic prescribing throughout the care spectrum, the discharge phase from hospitalization is a notable contributor to antibiotic overuse. 

Thus, it becomes imperative to improve antibiotic prescribing by optimizing antibiotic selection, reassessing antibiotic treatment, and using the shortest effective duration of therapy post-discharge.  

#Antibioticresistance #AntimicrobialAwarenessWeek #AntimicrobialResistance #WorldAntimicrobialAwarenessWeek #WAAW #WAAW2023 #AMR

	Jun '22	Mar '23	Sep '23	Mar '24	Jun '24	Sep '24
account payables		938M -	761.16M -	944.35M -		821.72M -
accumulated other comprehensive income loss			104.62M -		15.27B -
cash and cash equivalents	-1.61B -	34.99M 102.17%	60.78M -	470.24M -		74M -
cash and short term investments	1.61B -	1.72B 6.42%	2.52B -	2.91B -	2.82B 3.12%	3.18B 13.00%
common stock		104.62M -	104.62M -	104.62M -		104.62M -
deferred revenue			635.96M -	54.94M -
deferred revenue non current
deferrred tax liabilities non current		234.40M -	246.93M -	280.64M -		291.13M -
goodwill
goodwill and intangible assets		2M -	5.40M -	3.20M -		7.84M -
intangible assets		2M -	5.40M -
inventory		2.12B -	2.20B -	2.08B -		2.50B -
long term debt		64M -	26.71M -	18.87M -		16.07M -
long term investments		-1.68B -	88.98M -	70.28M -		-3.01B -
net debt	1.61B -	280.48M 82.62%	168.89M -	-372.87M -		-39.76M -
net receivables		3.43B -	2.67B -	3.50B -
other assets			0.00 -	1 -
other current assets		7.12M -	171.83M -	479.42M -		3.66B -
other current liabilities		728.99M -	710.36M -	343.76M -		558.09M -
other liabilities
other non current assets		1.89B -	83.44M -	106.51M -	-2.82B 2,744.47%	3.24B 215.11%
other non current liabilities		22.97M -	19.05M -	19.56M -	-15.27B 78,145.37%	15.33M 100.10%
othertotal stockholders equity		1.11B -	13.33B -	15.16B -		15.80B -
preferred stock
property plant equipment net		7.65B -	7.78B -	7.86B -		8.06B -
retained earnings		11.68B -
short term debt		251.47M -	202.95M -	78.51M -		18.17M -
short term investments	3.23B -	1.68B 47.88%	2.45B -	2.44B -		3.11B -
tax assets			64.19M -	-1 -		3.01B -
tax payables		89.99M -		54.94M -		19.16M -
total assets		15.14B -	15.51B -	17.01B -		17.64B -
total current assets	1.61B -	7.28B 350.90%	7.56B -	8.96B -	2.82B 68.57%	9.35B 231.83%
total current liabilities		1.92B -	1.67B -	1.42B -		1.42B -
total debt		315.47M -	229.67M -	97.38M -		34.24M -
total investments	3.23B -	1.25M 99.96%	88.98M -	2.51B -		95.50M -
total liabilities		2.24B -	1.97B -	1.74B -	-15.27B 977.06%	1.74B 111.40%
total liabilities and stockholders equity		15.14B -	15.51B -	17.01B -		17.64B -
total non current assets		7.86B -	7.95B -	8.04B -	-2.82B 135.01%	8.30B 394.57%
total non current liabilities		321.37M -	292.70M -	319.08M -	-15.27B 4,884.58%	322.53M 102.11%
total stockholders equity	11.03B -	12.90B 16.93%	13.54B -	15.27B -	15.27B 0%	15.90B 4.17%

CONC

COM:CONCORDBIOTECH

Concord Biotech

Last Close

2,031.55

25/11 09:20

Market Cap

176.73B

Beta: -

Volume Today

7.43K

Avg: -

Preview